Krystal Biotech, Inc. Share Price
KRYSKrystal Biotech, Inc. Stock Performance
Open $249.94 | Prev. Close $250.91 | Circuit Range N/A |
Day Range $249.94 - $258.30 | Year Range $122.80 - $297.85 | Volume 12,996 |
Average Traded $254.35 |
Krystal Biotech, Inc. Share Price Chart
About Krystal Biotech, Inc.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Krystal Biotech, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
18-Mar-26 | $254.44 | $250.96 | -2.12% |
17-Mar-26 | $253.22 | $256.39 | +2.56% |
16-Mar-26 | $251.40 | $249.98 | +1.06% |
13-Mar-26 | $254.86 | $247.37 | -1.52% |
12-Mar-26 | $249.47 | $251.18 | -1.51% |
11-Mar-26 | $256.08 | $255.02 | -1.14% |
10-Mar-26 | $259.31 | $257.95 | -0.37% |